Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
On March 10, 2025, Acadia Healthcare Company, Inc. (the “Company”), entered into an Indenture, dated as of March 10, 2025 (the “Indenture”), by and among the Company, the guarantors party thereto (the “Guarantors”) and U.S. Bank National Association, as trustee (the “Trustee”), in connection with the sale and issuance of $550 million aggregate principal amount of 7.375% Senior Notes due 2033 (the “Notes”) to J.P. Morgan Securities LLC and certain other initial purchasers in a private offering (the “Offering”) exempt from registration requirements under the Securities Act of 1933, as amended (the “Securities Act”) to qualified institutional buyers in the United States, as defined in Rule 144A under the Securities Act, and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act.
Issuer evidence: On March 10, 2025, Acadia Healthcare Company, Inc. (the “Company”), entered into an Indenture, dated as of March 10, 2025 (the “Indenture”), by and among the Company, the guarantors party thereto (the “Guarantors”) and U.S. Bank National Association, as trustee (the “Trustee”), in connection with the sale and issuance of $550 million aggregate principal amount of 7.375% Senior Notes due 2033 (the “Notes”) to J.P. Morgan Securities LLC and certain other initial purchasers in a private offering (the “Offering”) exempt from registration requirements under the Securities Act of 1933, as amended (the “Securities Act”) to qualified institutional buyers in the United States, as defined in Rule 144A under the Securities Act, and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act.
Supporting evidence: The Notes will mature on March 15, 2033 and bear interest at a rate of 7.375% per annum, payable semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2025. The Notes are the Company’s senior unsecured obligations and are fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by the Guarantors.
Supporting evidence: On March 10, 2025, Acadia Healthcare Company, Inc. (the “Company”), entered into an Indenture, dated as of March 10, 2025 (the “Indenture”), by and among the Company, the guarantors party thereto (the “Guarantors”) and U.S. Bank National Association, as trustee (the “Trustee”), in connection with the sale and issuance of $550 million aggregate principal amount of 7.375% Senior Notes due 2033 (the “Notes”) to J.P. Morgan Securities LLC and certain other initial purchasers in a private offering (the “Offering”) exempt from registration requirements under the Securities Act of 1933, as amended (the “Securities Act”) to qualified institutional buyers in the United States, as defined in Rule 144A under the Securities Act, and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act.
Supporting evidence: On March 10, 2025, Acadia Healthcare Company, Inc. (the “Company”), entered into an Indenture, dated as of March 10, 2025 (the “Indenture”), by and among the Company, the guarantors party thereto (the “Guarantors”) and U.S. Bank National Association, as trustee (the “Trustee”), in connection with the sale and issuance of $550 million aggregate principal amount of 7.375% Senior Notes due 2033 (the “Notes”) to J.P. Morgan Securities LLC and certain other initial purchasers in a private offering (the “Offering”) exempt from registration requirements under the Securities Act of 1933, as amended (the “Securities Act”) to qualified institutional buyers in the United States, as defined in Rule 144A under the Securities Act, and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.54×
Peer median 1.52×
EV/EBIT
—
Peer median 18.08×
P/E (TTM)
—
Peer median 21.25×
EV/Adj. EBITDA (FY2025)
8.52×
Peer median 13.74×
Peer medians compare against the 33 similar-size Medical Care Facilities companies (of 56 listed).
EV/Adj. EBITDA uses
the company-stated
“Adjusted EBITDA”,
extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.
Valuation over time computed as of each quarter's filing date
EV/Adj. EBITDA uses
the company-stated
“Adjusted EBITDA”,
extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
Component
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
United States Facilities
$3,312,769,000
$3,153,963,000
$2,928,738,000
$2,610,399,000
$2,314,394,000
$2,089,929,000
$2,008,381,000
$1,904,695,000
By Product & Service (USD)
Component
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Acute Inpatient Psychiatric Facilities
$1,830,324,000
$1,678,266,000
$1,489,248,000
$1,330,757,000
$1,126,872,000
$984,609,000
$912,097,000
$814,124,000
Specialty Treatment Facilities
$567,196,000
$592,023,000
$614,220,000
$564,671,000
$510,929,000
$452,805,000
$788,232,000
$761,017,000
Comprehensive Treatment Centers
$567,176,000
$537,886,000
$500,242,000
$419,940,000
$385,635,000
$349,217,000
—
—
Residential Treatment Centers
$348,073,000
$345,788,000
$325,028,000
$295,031,000
$283,169,000
$281,158,000
$286,959,000
$293,053,000
Product And Service Other
—
—
—
—
$7,789,000
$22,140,000
$21,093,000
$36,501,000
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
